Approved Research This page provides a searchable list of all research protocols that have been reviewed and approved by the Uganda National Council for Science and Technology(UNCST).
Search By Approval Date:
Clear Filter Total: 6,033
Name Title Nationality Approval Date Expiry Date Field of Science/Classification Trial Type Research Type  
Winnie  Muyindike R
ID: UNCST-2021-R013558
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure for Individuals on TLD in Sub-Saharan Africa.(RESOLVE)
REFNo: HS2620ES

Aim 2: Use simulation modeling to examine the clinical impact, costs, and cost-effectiveness of strategies to improve viral suppression after virologic failure on TLD. We will populate the previously validated Cost-Effectiveness of Preventing AIDS Complications-International (CEPAC-I) model with the novel clinical trial data from Aim 1 to project long-term clinical outcomes and cumulative lifetime costs. We will then compare the cost-effectiveness of the three strategies evaluated in Aim 1 for addressing virologic failure among people treated with first-line TLD in Uganda or South Africa. ,Aim 1: Conduct a randomized clinical trial to determine the optimal strategy for management of virologic failure on first-line TLD in SSA. We will recruit 648 adolescents and adults with two viral loads >1,000 copies/mL while on first-line TLD for at least 12 months, who are in care at one of six public-sector HIV clinics in Uganda or South Africa. We will randomize participants to one of the following strategies, stratified by clinic and prior NNRTI-exposure: a) Maintenance on TLD with switch to protease inhibitor (PI)-based second-line ART if virologic failure persists past six months; b) Individualized Care, with regimen choice based on results of genotypic resistance tests and urine tenofovir assays; or c) Immediate Switch to PI-based second-line ART. The primary outcome will be viral suppression (<50 copies/mL) at 48 weeks post-enrollment using the FDA snapshot definition. We hypothesize that rates of viral suppression at 48 weeks will be higher in the Individualized Care arm than in the Maintenance on TLD and Immediate Switch arms.,
Uganda 2023-02-09 11:06:56 2026-02-09 Medical and Health Sciences Clinical Trial Non-degree Award
Bruno Sserunkuuma
ID:
PREVALENCE AND FACTORS ASSOCIATED WITH ADVERSE MATERNAL OUTCOMES OF SPINAL INDUCED HYPOTESION AMONG WOMEN UDERGOING CEASAREAN DELIVERIES AT MBARARA REGIONAL REFERRAL HOSPITAL.
REFNo: HS2562ES

General objective.
To determine the prevalence and factors associated with adverse maternal outcome of spinal induced hypotension among women undergoing caesarean deliveries at Mbarara Regional Referral Hospital
Specific objectives
1.To determine the prevalence of mothers that develop spinal induced hypotension undergoing caesarean deliveries at Mbarara Regional Referral Hospital.
2.To determine the factors associated with spinal induced hypotension among mothers undergoing caesarean deliveries at Mbarara Regional Referral Hospital
3.To describe the adverse maternal outcomes among women with spinal induced hypotension


Uganda 2023-02-07 11:14:38 2026-02-07 Medical and Health Sciences Non-Clinical Trial Degree Award
DIANA NABUKENYA KASOZI
ID:
TIME TO TREATMENT INITIATION AMONG PATIENTS TREATED FOR DR-TB IN UGANDA
REFNo: HS2653ES

1. To determine the socio-demographic factors associated with drug-resistant tuberculosis (DR-TB) treatment delay among DR-TB patients in order to achieve a successful or unsuccessful treatment outcome in Uganda.
2. To investigate what clinical factors associated with DR-TB treatment delay among DR-TB patients in order to attain a successful or unsuccessful treatment outcome in Uganda.
3. Describe the structural factors associated with DR-TB treatment delay among DR-TB patients in order to achieve a successful or unsuccessful treatment outcome in Uganda.
4. To estimate the mean and median time to DR-TB treatment from the time of DR-TB diagnosis for patients on DR-TB treatment in Uganda.

Uganda 2023-02-06 17:25:58 2026-02-06 Medical and Health Sciences Non-Clinical Trial Degree Award
Nixon Niyonzima
ID: UNCST-2020-R014577
The Impact of HIV on the Breast Cancer Tumor Microenvironment
REFNo: HS2651ES

Compare the molecular profile of breast cancer tissue and blood using targeted sequencing from HIV+ women and HIV- women to identify potential HIV-associated features driving increased tumor aggressiveness.,Assess if the presence, spatial distribution, and/or the cellular phenotype of immune cells in the breast TME are consistent with HIV- associated immune dysfunction in WLWH compared to HIV- women,Identify features of HIV-associated immune dysfunction in blood and tumor tissue from WLWH with breast cancer that could promote tumorigenesis and progression.,
Uganda 2023-02-06 17:24:00 2026-02-06 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Shannon McMorrow
ID:
Photovoice assessment of integration, health, and healthcare experiences of urban Congolese refugee women in Kampala, Uganda
REFNo: HS2655ES

To generate in-depth, contextual evidence to inform policy and program improvements for Congolese refugee women in Kampala to prevent further marginaliation and negative health outcomes.
USA 2023-02-06 17:19:40 2026-02-06 Medical and Health Sciences Non-Clinical Trial Non-degree Award
View Sort By:

"A prosperous Science and Technology Led Ugandan Society."